UBS Group
NTLA icon

UBS Group’s Intellia Therapeutics NTLA Stock Holding History

UBS Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4M Sell
2,152,912
-536,574
-20% -$7.51M ﹤0.01% 2068
2026
Q1 		$34.5M Buy
2,689,486
+1,829,934
+213% +$23.3M 0.01% 2019
2025
Q4 		$7.73M Sell
859,552
-248,634
-22% -$3.42M ﹤0.01% 3566
2025
Q3 		$19.1M Buy
1,108,186
+227,313
+26% +$2.8M ﹤0.01% 2614
2025
Q2 		$8.26M Sell
880,873
-245,931
-22% -$2.02M ﹤0.01% 3298
2025
Q1 		$8.01M Sell
1,126,804
-614,964
-35% -$6.21M ﹤0.01% 3285
2024
Q4 		$20.3M Buy
1,741,768
+1,463,336
+526% +$22.8M ﹤0.01% 2304
2024
Q3 		$5.72M Buy
278,432
+22,881
+9% +$528K ﹤0.01% 2942
2024
Q2 		$5.72M Sell
255,551
-76,035
-23% -$1.81M ﹤0.01% 2738
2024
Q1 		$9.12M Buy
331,586
+57,062
+21% +$1.58M ﹤0.01% 2349
2023
Q4 		$8.37M Buy
274,524
+150,517
+121% +$4.33M ﹤0.01% 2257
2023
Q3 		$3.92M Sell
124,007
-10,862
-8% -$421K ﹤0.01% 2811
2023
Q2 		$5.5M Buy
134,869
+45,495
+51% +$1.84M ﹤0.01% 2485
2023
Q1 		$3.33M Sell
89,374
-92,237
-51% -$3.62M ﹤0.01% 2905
2022
Q4 		$6.34M Buy
181,611
+132,643
+271% +$6.31M ﹤0.01% 2265
2022
Q3 		$2.74M Buy
48,968
+2,054
+4% +$127K ﹤0.01% 2875
2022
Q2 		$2.43M Sell
46,914
-52,265
-53% -$2.65M ﹤0.01% 2979
2022
Q1 		$7.21M Sell
99,179
-15,969
-14% -$1.35M ﹤0.01% 2203
2021
Q4 		$13.6M Buy
115,148
+50,694
+79% +$6.35M ﹤0.01% 1872
2021
Q3 		$8.65M Buy
64,454
+15,039
+30% +$2.28M ﹤0.01% 2156
2021
Q2 		$8M Sell
49,415
-2,696
-5% -$210K ﹤0.01% 2230
2021
Q1 		$4.18M Sell
52,111
-73,838
-59% -$4.96M ﹤0.01% 2804
2020
Q4 		$6.85M Buy
125,949
+50,413
+67% +$1.83M ﹤0.01% 2159
2020
Q3 		$1.5M Sell
75,536
-10,204
-12% -$213K ﹤0.01% 3323
2020
Q2 		$1.8M Buy
85,740
+4,071
+5% +$69.2K ﹤0.01% 2976
2020
Q1 		$999K Sell
81,669
-33,065
-29% -$445K ﹤0.01% 3348
2019
Q4 		$1.68M Sell
114,734
-110,980
-49% -$1.54M ﹤0.01% 3722
2019
Q3 		$3.01M Buy
225,714
+71,391
+46% +$1.14M ﹤0.01% 2884
2019
Q2 		$2.53M Buy
154,323
+13,187
+9% +$207K ﹤0.01% 2937
2019
Q1 		$2.41M Sell
141,136
-63,465
-31% -$946K ﹤0.01% 2835
2018
Q4 		$2.79M Buy
204,601
+66,702
+48% +$1.24M ﹤0.01% 2693
2018
Q3 		$3.95M Buy
137,899
+16,994
+14% +$494K ﹤0.01% 2576
2018
Q2 		$3.31M Sell
120,905
-70,711
-37% -$1.71M ﹤0.01% 2710
2018
Q1 		$4.04M Buy
191,616
+108,878
+132% +$2.68M ﹤0.01% 2509
2017
Q4 		$1.59M Buy
82,738
+13,114
+19% +$303K ﹤0.01% 3386
2017
Q3 		$1.73M Buy
69,624
+7,320
+12% +$138K ﹤0.01% 3250
2017
Q2 		$997K Buy
62,304
+1,369
+2% +$19.1K ﹤0.01% 3616
2017
Q1 		$859K Buy
60,935
+49,480
+432% +$664K ﹤0.01% 3667
2016
Q4 		$150K Buy
11,455
+10,038
+708% +$151K ﹤0.01% 4989
2016
Q3 		$24K Buy
1,417
+417
+42% +$8.07K ﹤0.01% 6152
2016
Q2 		$21K Buy
+1,000
New +$26.6K ﹤0.01% 6263

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

UBS Group's NTLA Position: Q2 2026 in Review

UBS Group reduced its Intellia Therapeutics (NTLA) stake by 20% in Q2 2026, selling an estimated $7.51M and leaving 2,152,912 shares worth $36.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

UBS Group first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • UBS Group held 2,152,912 shares of Intellia Therapeutics worth $36.4M as of Q2 2026.
  • UBS Group sold 536,574 Intellia Therapeutics shares in Q2 2026, an estimated $7.51M.
  • Intellia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2068 holding.
  • UBS Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.